Skip to content
Screener

Vaxcyte, Inc. PCVX Q2 2025 earnings

Reported August 6, 2025 · Before market open

EPS-$1.22Miss by $0.10
EPS estimate-$1.12

Next report

Nov 3, 2026 (in 3 months)
Revenue estimate$12.5M
EPS estimate-$2.12

Financials

Q2 2025

Income statement

See full
Operating income-$226.2M-47.9%
Net income-$166.6M-29.4%
EPS (diluted)-$1.22-10.9%

Balance sheet

See full
Cash & equivalents$308.1M-40.7%
Total debt$85.8M+236%
Total equity$3.1B+54.6%
Total assets$3.3B+58.4%

Cash flow

See full
Operating cash flow-$121.2M+0.2%
CapEx$1.8M-76.7%
Free cash flow-$123.0M+4.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$4.4B-47.9%
Enterprise value$4.18B-47.4%

Returns & leverage

See full
Return on equity-21.7%-4.4pp
Debt / equity0×0.0×
Current ratio11.1×-6.8×

FAQ

When did Vaxcyte, Inc. report Q2 2025 earnings?
Vaxcyte, Inc. (PCVX) reported Q2 2025 earnings on August 6, 2025 before market open.
What were Vaxcyte, Inc.'s Q2 2025 revenue and EPS?
Vaxcyte, Inc. reported eps of $-1.22 for Q2 2025.
Did Vaxcyte, Inc. beat estimates in Q2 2025?
EPS missed the consensus estimate of $-1.12 by $0.10.
How did Vaxcyte, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 10.9% from $-1.10.
Where can I find Vaxcyte, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001649094-25-000096) and the 10-Q periodic report (0001649094-25-000098) directly on SEC EDGAR. The filing index links above go to sec.gov.